Third-Generation IVF Is Not an 'Upgrade'—Its Core Value Is 'Healthy-Child Selection' Many families mistakenly think third-generation IVF is an 'upgraded' version of the first/second generations. In fact, the three are different solutions for different problems; the core of the third generation is preimplantation genetic testing (PGT) for healthy-child selection. First generation (IVF) addresses female-factor infertility (tubal blockage, ovulation disorders) by fertilizing eggs and sperm in vitro; second generation (ICSI) addresses severe male-factor infertility by injecting a single sperm; third generation (PGT) screens the blastocyst (day 5–6) for genetic/chromosome conditions before transfer, selecting healthy embryos to avoid chromosome abnormalities and single-gene diseases.

Note: fourth-generation IVF (oocyte/follicular-fluid exchange) is not a clinical routine anywhere and is explicitly prohibited in China; families should beware and not cross this line. Third-generation IVF is mainly for four groups: couples with chromosome abnormalities (balanced/Robertsonian translocation); carriers of single-gene diseases (thalassemia, hemophilia, albinism); advanced-age women (usually ≥35), to reduce aneuploidy risk and support pregnancy while reducing miscarriage; and families with recurrent miscarriage or repeated transfer failure.

Ms. Lin, 38, a beneficiary, had two missed miscarriages and, via third-generation IVF, screened three healthy embryos and delivered twins. 'The extra 30,000 yuan for screening was worth it compared with repeated miscarriages.' The higher cost of third-generation IVF lies in the PGT testing.

Main PGT types: PGT-A (chromosome number, reduces miscarriage/Down-syndrome risk, prioritizes implantable embryos); PGT-M (specific single-gene disease, for carrier couples); PGT-SR (structural rearrangement, for known structural issues); PGT-P (polygenic common chronic diseases, e.g., diabetes, heart disease risk).

Cost Breakdown (2025, China; pre-reimbursement, for reference) National average total for third-generation IVF: RMB 80,000–150,000, varying by region, hospital, condition, and protocol. 1) Pre-op tests: ~5,000–10,000. 2) Stimulation drugs: ~15,000–25,000 (imported ~10,000–20,000; domestic ~5,000–10,000). 3) Retrieval & lab culture: ~20,000–30,000. 4) Core PGT testing: ~20,000–40,000 (per embryo ~3,000–5,000). 5) Transfer & luteal support: ~5,000–10,000. Extras: private hospitals 10%–20% above public tertiary; long protocol +3,000–5,000 vs antagonist; advanced age +20%–30%; each extra embryo +~3,000; ERA ~6,000–8,000; mitochondrial support ~5,000–10,000.

Insurance & Regional Differences (early 2025) 28 provinces cover some ART; third-generation reimbursement varies. Beijing (from 2026-01-01) covers third-generation IVF at 80% for eligible couples (e.g., woman <35, married). Guangxi (from 2025-11-01): 70% (employee) / 50% (resident). Ningxia (from 2025-10-15): ~6,000–8,000 per cycle. PGT and embryo storage usually remain out-of-pocket (~30,000–50,000).

Post-Reimbursement Example—Shanghai Ms. Wang, 38, with balanced translocation, used PGT-SR at a public tertiary hospital; 8 blastocysts tested. Total ~78,000: exams/stimulation ~15,000; retrieval/IVF/culture ~25,000; PGT ~30,000; transfer/luteal ~8,000. Under Shanghai's 2025-06 policy, reimburseable items (12 core services) totaled 45,000; after 10% self-pay on Class B, base 40,500; at 80% employee rate, insurance paid 32,400; out-of-pocket ~45,600 (about 45,000–50,000), saving ~32,000.

Planning Tips Check local insurance first; public hospitals are usually cheaper and more transparent; some offer installments; for multiple attempts, screen selectively; watch for packages. As ART gradually enters national insurance, more families can use third-generation IVF—though PGT stays out-of-pocket, local policies already ease the burden. Plan budget and choose a licensed institution. (More IVF/overseas-birth info: scan the QR code or call 181-0136-5219.)